Evaluation of the analytical performance characteristics of the Bayer ACS:180® B-type natriuretic peptide (BNP) assay

Clinica Chimica Acta

Volumn 353, Issue 1-2, 2005, Pages 147-155

  Wians Jr , Frank H ^a   Wilson, Betty Anne ^b   Grant, Andrew ^c   Bailey, Jonathan ^a   Gheorghiu, Ionela ^c   Conarpe, Carla ^d   Mindicino, Henry ^d   Thakur, Kiran ^d   Belenky, Alexander ^d   Despres, Normand ^d   Bluestein, Barry ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Northern Westchester Hospital   (United States)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^d BAYER CORPORATION   (United States)

Author keywords

Analytical performance; B type natriuretic peptide assay; Bayer ACS:180

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; EDETIC ACID; REAGENT;

ACCURACY; ARTICLE; BLOOD LEVEL; CHEMOLUMINESCENCE; CONTROLLED STUDY; DILUTION; HUMAN; IMMUNOASSAY; IMMUNOCHEMILUMINESCENT ASSAY; INTERMETHOD COMPARISON; PRIORITY JOURNAL;

EID: 13444291248     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2004.10.015     Document Type: Article

References (24)

1. E.R. Levin, D.G. Gardner, and W.K. Samson Natriuretic peptides N. Engl. J. Med. 339 1998 321 328
2. A.S. Maisel, P. Krishsaswamy, R.M. Nowak, J. McCord, J.E. Hollander, and P. Duc Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure N. Engl. J. Med. 347 2002 161 167
3. A. Luchner, C. Hengstenberg, H. Lowel, J. Trawinski, M. Baumann, and G.A. Riegger N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function Hypertension 39 2002 99 104
4. P.A. McCullough, T. Omland, and A.S. Maisel B-type natriuretic peptides: a diagnostic breakthrough for clinicians Rev. Cardiovasc. Med. 4 2003 72 80
5. T. Maack Receptors of natriuretic peptides J. Laragh Hypertension: Pathophysiology, Diagnosis, and Management 2nd edn. 1995 Raven Press New York 833 840
6. T.M. Ambrose Review of the clinical utility of NT-proBNP in the diagnosis, prognosis, and therapy monitoring of patients with congestive heart failure J. Clin. Ligand Assay 25 2002 160 166
7. T. Mueller, A. Gegenhuber, W. Poelz, and M. Haltmayer Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease Clin. Chim. Acta 341 2004 41 48
8. A. Hammerer-Lercher, E. Neubauer, S. Mηller, O. Pachinger, Puschendorf Bernd, and J. Mair Head-to-head comparison of N-terminal pro-btain natriuretic peptide, brain natriuretic peptide, and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction Clin. Chim. Acta 310 2001 193 197
9. R. Pfister, M. Scholz, K. Wielckens, E. Erdmann, and C.A. Schneider The value of natriuretic peptides NT-pro-BNP and BNP for the assessment of left-ventricular volume and function: a prospective study of 150 patients Dtsch. Med. Wochenschr. 127 2002 2605 2609
10. A.H.B. Wu B-type natriuretic peptide for congestive heart failure J. Clin. Ligand Assay 25 2002 155 159
11. S.J. Wieczorek, A.H. Wu, R. Christenson, P. Krishnaswamy, S. Gottlieb, and T. Rosano A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation Am. Heart J. 144 2002 834 839
12. T. Tsutamoto, A. Wada, K. Maeda, T. Hisanaga, Y. Maeda, and D. Fukai Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction Circulation 96 1997 509 516
13. S. Kruger, J. Graf, D. Kunz, T. Stickel, P. Hanrath, and U. Janssens Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure J. Am. Coll. Cardiol. 40 2002 718 722
14. J.A. de Lemos, D.K. Mcguire, and M.H. Drazner B-type natriuretic peptide in cardiovascular disease Lancet 362 2003 316 322
15. A.H.B. Wu, M. Packer, A. Smith, R. Bijou, D. Fink, and J. Mair Analytical and clinical evaluation of the Bayer ADVIA Centaur® automated B-type natriuretic peptide assay in patients with heart failure: a multisite study Clin. Chem. 50 2004 867 873
16. Bayer ADVIA Centaur Assay Manual- BNP Part #131073, F. Rev, December 2003, Bayer L.LC. Healthcare, Diagnostics Division, Tarrytown, NY.
17. A. Koch, and H. Singer Normal values of B-type natriuretic peptide in infants, children, and adolescents Heart (British Cardiac Society) 89 2003 875 878
18. H. Ruskoaha Cardiac hormones as diagnostic tools in heart failure Endocr. Rev. 24 2003 341 356
19. A. Belenky, A. Smith, B. Zhang, S. Lin, N. Despres, and A.H.B. Wu The effect of class specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma Clin. Chim. Acta 340 2004 163 172
20. T. Tsjui, K. Inouye, M. Kono, K. Igano, Monocolonal antibody recognizing the C terminus of hBNP. US Patent No: 6,677,124B2; Jan 13, 2004.
21. National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices; approved guideline. NCCLS guideline EP-5A. Wayne, PA:NCCLS, February, 1999.
22. Abbott AxSYM® BNP Package Insert, List Number: 8G82-20, February 2004, Abbott Laboratories, Diagnostics Division, Abbott Park, IL.
23. Biosite® Triage® BNP Test Package Insert, Part No: 22173, rev 2002, Biosite Incorporated, San Diego, CA.
24. B. Bluestein, D. Morrow, M. Sabatine, N. Despres, and A. Belenky Evaluation of B natriuretic peptide BNP stability after collection and storage in glass and plastic tubes Clin. Chem. Lab. Med. 40 2002 S313